electroCore

Historical price data

Founded in 2005, electroCore is a leader in non-invasive neuromodulation, developing and commercializing its gammaCore nVNS platform. The company has achieved FDA clearances, CE marks, and other international approvals for its reusable medical device, generating revenue while expanding its clinical pipeline into new indications like PTSD and metabolic disorders. With a strong intellectual property portfolio of over 200 patents and a seasoned leadership team, electroCore aims to establish nVNS as a foundational therapy across multiple therapeutic areas.

Proprietary non-invasive vagus nerve stimulation (nVNS) platform, delivered via a handheld device (gammaCore) that stimulates the vagus nerve through the skin to modulate neurological and inflammatory pathways without drugs.

Total raised: $110M

electroCore competes with implantable VNS makers (e.g., LivaNova), other neuromodulation device companies, and dominant pharmaceutical firms in migraine and other indications. Its primary differentiation is the non-invasive, patient-administered, and drug-free nature of its gammaCore therapy, offering a unique alternative or adjunct to existing treatments.